FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

_					
$\sim$	MR	$\Lambda D$	00	$\cap$	/ N I

OMB Number:	3235-0287
Estimated average burden	
houre per reenonce:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MIGAUSKY GEORGE V			2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [ IMVT ]	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner						
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/12/2023	71	Officer (give title below)	Other (specify below)				
320 W 37TH STREET, 6TH FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check App							
(Street) NEW YORK NY 10018		10018		X	Form filed by One Reporting Form filed by More than One					
- TOUR INT TOUTS			Rule 10b5-1(c) Transaction Indication							
(City) (State) (Zip)		(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)			tion str.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock <sup>(1)</sup>	04/12/2023		A		12,523(2)	A	\$0	122,508	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$14.7	04/12/2023		A		16,260		(3)	04/12/2033	Common Stock	16,260	\$0	16,260	D	

### Explanation of Responses:

- 1. Represents the number of shares underlying restricted stock units awards ("RSUs").
- 2. The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- 3. The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date.

## Remarks:

/s/ Eva Renee Barnett, attorney-infact for George V. Migausky 04/14/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.